Cargando…
FRI092 Rationale And Design Of The Balance Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Olezarsen In Patients With Familial Chylomicronemia Syndrome
Disclosure: V. Alexander: Employee; Self; Ionis Pharmaceuticals Inc. E. Karwatowska-Prokopczuk: Employee; Self; Ionis Pharmaceuticals Inc. E.S. Stroes: Other; Self; Akcea Therapeutics, Ionis Pharmaceuticals Inc., Amgen Inc, Novo Nordisk, AstraZeneca, Esperion. C. Ballantyne: Speaker; Self; Ionis Pha...
Autores principales: | Alexander, Veronica, Karwatowska-Prokopczuk, Ewa, Stroes, Erik S G, Ballantyne, Christie, Ginsberg, Henry N, Xia, Shuting, Witztum, Joseph, Tsimikas, Sam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555401/ http://dx.doi.org/10.1210/jendso/bvad114.606 |
Ejemplares similares
-
FRI105 Getting Fam-iliar With Familial Chylomicronemia Syndrome: A Case Report
por: Jimenez, Aaron-Ross, et al.
Publicado: (2023) -
Treatment with Volanesorsen, a 2′-O-Methoxyethyl-Modified Antisense Oligonucleotide Targeting APOC3 mRNA, Does Not Affect the QTc Interval in Healthy Volunteers
por: Watts, Lynnetta M., et al.
Publicado: (2020) -
Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia
por: Gaudet, Daniel, et al.
Publicado: (2020) -
Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk
por: Tardif, Jean-Claude, et al.
Publicado: (2022) -
Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles
por: O’Dea, Louis St L, et al.
Publicado: (2019)